Perifosine

Open November ’12

Title: A Phase 3 randomized study to assess the efficacy and safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib.

Population: Patients who received 1 – 4 prior treatments and are not refractory to Bortezomib (No disease progression within 60 days of Bortezomib treatment).

Resource Links:

http://www.cancer.gov/clinicaltrials/search/view?cdrid=658570&version=HealthProfessional

http://clinicaltrials.gov/ct2/show/NCT01002248?term=perifosine+AND+multiple+myeloma&rank=2

« Back